Severe Red Blood Cell & Hemoglobin Pathologies

Beta-Thalassemia Major (Cooley's Anemia)

Autosomal Recessive Microcytic Hemolytic Anemia

Primary risk age: Infants (Presents within the first 6 to 12 months of life as fetal hemoglobin declines)

Urgency: Severe
Typical age: Infants (Presents within the first 6 to 12 months of life as fetal hemoglobin declines)
Body system: Hematological System

Typical course: This is a lifelong genetic disorder requiring ongoing medical treatment; transfusion therapy is a monthly requirement.

Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13

1. Summary & Pathophysiology

Autosomal Recessive Microcytic Hemolytic Anemia

Pathophysiology (Development Path)

The lack of beta-globin chains leads to an excess of alpha-globin chains, which aggregate and form insoluble precipitates in developing red blood cells. This causes severe ineffective erythropoiesis in the bone marrow and premature destruction of red cells in the spleen, driving profound anemia and extramedullary hematopoiesis.

Primary Causes & Etiology

Mutations or deletions in the beta-globin gene on chromosome 11, leading to a complete absence of beta-globin chain synthesis.

2. Symptom Continuum

Early Onset Signs
Progressive pallor, irritability, poor feeding, and failure to thrive in late infancy.
Progressive Phase
Hepatosplenomegaly (due to red cell destruction and blood cell production outside the marrow), mild jaundice, and skeletal changes, including frontal bossing and prominent maxilla ("thalassemia facies" due to marrow expansion).
Severe Indicators
Severe growth failure, pathological fractures, high-output heart failure, and systemic iron overload (hemosiderosis) from chronic blood transfusions, which damages the heart, liver, and endocrine glands.

3. Clinical Verification

Hemoglobin electrophoresis showing a complete absence or severe reduction of HbA, with elevated HbF. Complete blood count reveals severe microcytic, hypochromic anemia.

4. Care & Elements Plan

Primary Care Treatment Plan

Lifelong, regular blood transfusions every 3-4 weeks to maintain hemoglobin levels. Initiate iron chelation therapy once iron overload develops (after 10-20 transfusions) to prevent organ damage.

Home Support Elements

Maintain compliance with regular transfusion and daily chelation schedules. Monitor for signs of infection (especially if the spleen has been removed).

Generic Active Ingredients (No Brands)

Deferasirox or Deferoxamine (generic active iron-chelating ingredients to bind excess iron)
Folic acid (to support remaining erythropoiesis).

Lists active elements only. Never administer self-designed therapies.

5. Doctor Critical Lines

Critical Thresholds: When to See a Doctor

Seek immediate care if a child with thalassemia develops a fever, shows signs of respiratory distress, or exhibits extreme lethargy.

6. Vaccine & Prevention

Routine Prophylaxis (Prevention)

Genetic screening and prenatal counseling for couples of Mediterranean, Middle Eastern, or Asian descent who carry the thalassemia trait.

Immunization Context

Maintain all routine childhood vaccines; ensure pneumococcal and meningococcal immunizations are up to date if splenectomy is planned.

7. Timelines & Outlook

Active Timeline

This is a lifelong genetic disorder requiring ongoing medical treatment; transfusion therapy is a monthly requirement.

Expected Prognosis

Variable. With consistent transfusion and iron chelation, survival into the 30s or 40s is common. Hematopoietic stem cell transplantation is curative in selected cases.

Potential Untreated Complications

Iron overload causing cardiomyopathy, liver cirrhosis, diabetes, hypothyroidism, and hypogonadism. Transfusion-transmitted infections and splenomegaly.

Severe

Sickle Cell Anemia

Autosomal Recessive Hemoglobinopathy

Infants (Symptoms typically manifest after 6 months as fetal hemoglobin drops)

Moderate

G6PD Deficiency

X-Linked Red Blood Cell Enzymopathy

All ages (Inherited; typically triggered in infancy or childhood)